Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Dec 15, 2021
Date Accepted: Jul 26, 2022

The final, peer-reviewed published version of this preprint can be found here:

Digital Biomarker–Based Studies: Scoping Review of Systematic Reviews

Motahari-Nezhad H, Fgaier M, Mahdi Abid M, Péntek M, Gulácsi L, Zrubka Z

Digital Biomarker–Based Studies: Scoping Review of Systematic Reviews

JMIR Mhealth Uhealth 2022;10(10):e35722

DOI: 10.2196/35722

PMID: 36279171

PMCID: 9641516

Scoping review of systematic reviews of digital biomarker-based studies

  • Hossein Motahari-Nezhad; 
  • Meriem Fgaier; 
  • Mohamed Mahdi Abid; 
  • Márta Péntek; 
  • László Gulácsi; 
  • Zsombor Zrubka

ABSTRACT

Background:

Sensors and digital devices have revolutionized the process of measuring, collecting, and storing health data. Digital biomarkers are defined as objective, quantifiable, physiological, and behavioral measures contained in digital devices that are portable, wearable, implantable, or digestible. The clinical utility of digital biomarkers is being supported by an increasing body of research.

Objective:

The present study intends to investigate the scope of digital biomarker-based systematic reviews.

Methods:

The current scoping review was organized using PRISMA-ScR. Limiting the search to English full-text systematic reviews of digital biomarkers that included at least one randomized controlled trial involving a human population and reporting changes in participants' health status. PubMed and the Cochrane library were searched. Separately, two reviewers screened and selected records. In addition, the qualified papers' reference lists were examined for additional reviews. The World Health Organization's (WHO) classification systems for diseases (ICD-11), health interventions (ICHI), and bodily functions (ICF) were used to classify populations, interventions, and outcomes.

Results:

66 reviews met the inclusion criteria, mostly were published by authors from the United States of America (18, 27.28%). The most prevalent disease areas were Circulatory System (n=12, 18.18%) and External Causes (n=12, 18.18%). 27 and 23 interventions were connected to health-related behaviors and the circulatory system, respectively. Looking after one's health (physical activity) (n=22) and demographic changes (mortality) (n=19) were the most commonly reported outcomes. A substantial number of digital devices, mostly in the form of wearables (n=39/66, 59.09 %) were employed as interventions (n=43/66, 65.15 %). Position sensors (n=33/66) and heart /pulse rate sensors (n=32/66) were identified as the most prevalent types of sensors utilized to capture digital biomarkers.

Conclusions:

Digital biomarker clinical research encompasses a wide range of technologies, populations, interventions, and clinical outcomes, with cardiovascular and physical activity sensors being the most explored. This necessitates a more thorough examination of the strength and quality of evidence regarding the health consequences of digital biomarker-based therapy.


 Citation

Please cite as:

Motahari-Nezhad H, Fgaier M, Mahdi Abid M, Péntek M, Gulácsi L, Zrubka Z

Digital Biomarker–Based Studies: Scoping Review of Systematic Reviews

JMIR Mhealth Uhealth 2022;10(10):e35722

DOI: 10.2196/35722

PMID: 36279171

PMCID: 9641516

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.